Secondaries Announced 2.20.18

IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis.

If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today!

Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or opening trade) time period.

Company: Ascendis Pharma A/S
Symbol: ASND
Price: Last Trade $59.00
Trade Date: 2/22
Shares: 2.6 million ($150 million cash raise)
Underwriter(s): J.P. Morgan, BofA Merrill Lynch, Credit Suisse
Description: Ascendis Pharma is a biopharmaceutical company applying its TransCon technology to develop a pipeline of sustained release prodrug therapies with best-in-class profiles to address significant unmet medical needs in rare diseases.
Rating = Subscription Needed

Company: Dova Pharmaceuticals, Inc
Symbol: DOVA
Price: Last Trade $34.71
Trade Date: 2/23
Shares: 2.5 million
Underwriter(s): J.P. Morgan, Jefferies, Evercore ISI
Description: Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia.
Rating = Subscription Needed

Company: Aimmune Therapeutics, Inc
Symbol: AIMT
Price: Last Trade $34.96
Trade Date: 2/22
Shares: 4.3 million ($150m cash raise)
Underwriter(s): BofA Merrill Lynch, Cantor Fitzgerald, Piper Jaffray, Credit Suisse, RBC Capital Markets
Description: They are a clinical-stage biopharmaceutical company developing treatments for potentially life-threatening food allergies.
Rating = Subscription Needed